Article
AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance - MYNERVA-GIMEMA AML1919 trial.
Future oncology (London, England) - 1 Oct 2021
Mannelli Francesco, Gianfaldoni Giacomo, Guglielmelli Paola, Buccisano Francesco, Caporale Roberto, Chiarini Marco, Rossi Giuseppe, Venditti Adriano, Fazi Paola, Crea Enrico, Piciocchi Alfonso, Voso Maria Teresa, Vignetti Marco, Amadori Sergio, Vannucchi Alessandro Maria
Abstract excerpt
AMELIORATE is a Phase III, randomized trial aiming to personalize treatment intensity in FLT3-mutated acute myeloid leukemia. The current study provides an early appraisal of chemosensitivity based on peripheral blasts clearance, as assessed by multiparameter flow cytometry, from baseline to day 4 of induction. This biomarker was previously demonstrated to predict complete remission achievement and measurable...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.